Modified CAPOX (Capecitabine plus Oxaliplatin) Regimen Every Two Weeks as Second-Line Treatment in Patients with Advanced Colorectal Cancer Previously Treated with Irinotecan-Based Frontline Therapy : A Multicenter Phase II Study
- Author
- KAKOLYRIS, S1 ; SOUGLAKOS, J2 ; VARDAKIS, N2 ; GEORGOULIAS, V2 ; POLYZOS, A3 ; ARDAVANIS, A4 ; ZIRAS, N5 ; ATHANASIADIS, A5 ; VARTHALITIS, I6 ; AMARANTIDIS, K1 ; TSOUSIS, S7 ; VAMVAKAS, L2
[1] Department of Medical Oncology, University General Hospital of Alexandroupolis, Alexandroupolis, Greece
[2] Department of Medical Oncology, University General Hospital of Heraklion, Greece
[3] Medical Oncology Unit, Pathologic and Propedeutic Department, School of Medicine, University of Athens, Greece
[4] First Department of Medical Oncology, 'Agios Savas' Anticancer Hospital of Athens, Athens, Greece
[5] Department of Medical Oncology, General Hospital of Larissa, Larissa, Greece
[6] Department of Medical Oncology, General Hospital of Chania, Chania, Greece
[7] Department of Medical Oncology, Venizelion General Hospital of Heraklion, Heraklion, Greece
Hellenic Oncology Research Group (HORG), Greece - Source
Oncology. 2008, Vol 74, Num 1-2, pp 31-36, 6 p ; ref : 23 ref
- ISSN
- 0030-2414
- Scientific domain
- Medical oncology
- Publisher
- Karger, Basel
- Publication country
- Switzerland
- Document type
- Article
- Language
- English
- Author keyword
- Capecitabine Colorectal cancer Oxaliplatin Phase II study
- Keyword (fr)
- Anticancéreux Cancer colorectal Cancérologie Capécitabine Essai clinique phase II Etude multicentrique Homme Irinotécan Oxaliplatine Promédicament Protocole thérapeutique Stade avancé Traitement de deuxième intention Agent alkylant Camptothécine dérivé Cancer DNA topoisomerase Dérivé de la fluoropyrimidine Enzyme Inhibiteur de la topoisomérase I Inhibiteur enzyme Isomerases Pathologie de l'appareil digestif Pathologie de l'intestin Pathologie du côlon Pathologie du rectum Platine II Complexe Pyrimidine nucléoside Tumeur maligne
- Keyword (en)
- Antineoplastic agent Colorectal cancer Cancerology Capecitabine Phase II trial Multicenter study Human Irinotecan Oxaliplatin Prodrug Therapeutic protocol Advanced stage Second line treatment Alkylating agent Camptothecin derivatives Cancer DNA topoisomerase Fluoropyrimidine derivatives Enzyme Topoisomerase I inhibitor Enzyme inhibitor Isomerases Digestive diseases Intestinal disease Colonic disease Rectal disease Platinum II Complexes Pyrimidine nucleoside Malignant tumor
- Keyword (es)
- Anticanceroso Cancer de colon y recto Cancerología Capecitabina Ensayo clínico fase II Estudio multicéntrico Hombre Irinotecán Oxaliplatino Promedicamento Protocolo terapéutico Estadio avanzado Tratamiento de segunda línea Agente alquilante Camptothecin derivado Cáncer DNA topoisomerase Fluoropirimidina derivado Enzima Inhibidor topoisomerase I Inhibidor enzima Isomerases Aparato digestivo patología Intestino patología Colón patología Recto patología Platino II Complejo Pirimidina nucleósido Tumor maligno
- Classification
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B13 Gastroenterology. Liver. Pancreas. Abdomen / 002B13B Stomach. Duodenum. Small intestine. Colon. Rectum. Anus / 002B13B01 Tumors
- Discipline
- Gastroenterology. Liver. Pancreas. Abdomen Tumours
- Origin
- Inist-CNRS
- Database
- PASCAL
- INIST identifier
- 20457384
Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS
Access to the document
Install on your browser
DOI
10.1159/000138977 
https://dx.doi.org/10.1159/000138977
"O:13:\"PanistOpenUrl\":36:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000idc\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:17:\"10.1159\/000138977\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:229:\"Modified CAPOX (Capecitabine plus Oxaliplatin) Regimen Every Two Weeks as Second-Line Treatment in Patients with Advanced Colorectal Cancer Previously Treated with Irinotecan-Based Frontline Therapy : A Multicenter Phase II Study\";s:9:\"\u0000*\u0000jtitle\";s:8:\"Oncology\";s:9:\"\u0000*\u0000stitle\";s:8:\"Oncology\";s:7:\"\u0000*\u0000date\";s:4:\"2008\";s:9:\"\u0000*\u0000volume\";s:2:\"74\";s:8:\"\u0000*\u0000issue\";s:3:\"1-2\";s:8:\"\u0000*\u0000spage\";s:2:\"31\";s:8:\"\u0000*\u0000epage\";s:2:\"36\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0030-2414\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:9:\"KAKOLYRIS\";s:10:\"\u0000*\u0000aufirst\";s:1:\"S\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:11:{i:0;s:12:\"SOUGLAKOS, J\";i:1;s:11:\"VARDAKIS, N\";i:2;s:14:\"GEORGOULIAS, V\";i:3;s:10:\"POLYZOS, A\";i:4;s:12:\"ARDAVANIS, A\";i:5;s:8:\"ZIRAS, N\";i:6;s:15:\"ATHANASIADIS, A\";i:7;s:14:\"VARTHALITIS, I\";i:8;s:14:\"AMARANTIDIS, K\";i:9;s:10:\"TSOUSIS, S\";i:10;s:11:\"VAMVAKAS, L\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:229:\"Modified CAPOX (Capecitabine plus Oxaliplatin) Regimen Every Two Weeks as Second-Line Treatment in Patients with Advanced Colorectal Cancer Previously Treated with Irinotecan-Based Frontline Therapy : A Multicenter Phase II Study\";s:8:\"\u0000*\u0000place\";s:5:\"Basel\";s:6:\"\u0000*\u0000pub\";s:6:\"Karger\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"6\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Panist access
"O:12:\"IstexOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:17:\"10.1159\/000138977\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:229:\"Modified CAPOX (Capecitabine plus Oxaliplatin) Regimen Every Two Weeks as Second-Line Treatment in Patients with Advanced Colorectal Cancer Previously Treated with Irinotecan-Based Frontline Therapy : A Multicenter Phase II Study\";s:9:\"\u0000*\u0000jtitle\";s:8:\"Oncology\";s:9:\"\u0000*\u0000stitle\";s:8:\"Oncology\";s:7:\"\u0000*\u0000date\";s:4:\"2008\";s:9:\"\u0000*\u0000volume\";s:2:\"74\";s:8:\"\u0000*\u0000issue\";s:3:\"1-2\";s:8:\"\u0000*\u0000spage\";s:2:\"31\";s:8:\"\u0000*\u0000epage\";s:2:\"36\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0030-2414\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:9:\"KAKOLYRIS\";s:10:\"\u0000*\u0000aufirst\";s:1:\"S\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:11:{i:0;s:12:\"SOUGLAKOS, J\";i:1;s:11:\"VARDAKIS, N\";i:2;s:14:\"GEORGOULIAS, V\";i:3;s:10:\"POLYZOS, A\";i:4;s:12:\"ARDAVANIS, A\";i:5;s:8:\"ZIRAS, N\";i:6;s:15:\"ATHANASIADIS, A\";i:7;s:14:\"VARTHALITIS, I\";i:8;s:14:\"AMARANTIDIS, K\";i:9;s:10:\"TSOUSIS, S\";i:10;s:11:\"VAMVAKAS, L\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:229:\"Modified CAPOX (Capecitabine plus Oxaliplatin) Regimen Every Two Weeks as Second-Line Treatment in Patients with Advanced Colorectal Cancer Previously Treated with Irinotecan-Based Frontline Therapy : A Multicenter Phase II Study\";s:8:\"\u0000*\u0000place\";s:5:\"Basel\";s:6:\"\u0000*\u0000pub\";s:6:\"Karger\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"6\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Istex access
"O:16:\"UnpaywallOpenUrl\":35:{s:8:\"\u0000*\u0000email\";s:27:\"assistance-portail@inist.fr\";s:6:\"\u0000*\u0000fmt\";N;s:6:\"\u0000*\u0000doi\";s:17:\"10.1159\/000138977\";s:6:\"\u0000*\u0000pii\";N;s:7:\"\u0000*\u0000pmid\";N;s:9:\"\u0000*\u0000atitle\";N;s:9:\"\u0000*\u0000jtitle\";N;s:9:\"\u0000*\u0000stitle\";N;s:7:\"\u0000*\u0000date\";N;s:9:\"\u0000*\u0000volume\";N;s:8:\"\u0000*\u0000issue\";N;s:8:\"\u0000*\u0000spage\";N;s:8:\"\u0000*\u0000epage\";N;s:8:\"\u0000*\u0000pages\";N;s:7:\"\u0000*\u0000issn\";N;s:8:\"\u0000*\u0000eissn\";N;s:9:\"\u0000*\u0000aulast\";N;s:10:\"\u0000*\u0000aufirst\";N;s:9:\"\u0000*\u0000auinit\";N;s:10:\"\u0000*\u0000auinitm\";N;s:5:\"\u0000*\u0000au\";N;s:9:\"\u0000*\u0000aucorp\";N;s:7:\"\u0000*\u0000isbn\";N;s:8:\"\u0000*\u0000coden\";N;s:8:\"\u0000*\u0000genre\";N;s:7:\"\u0000*\u0000part\";N;s:9:\"\u0000*\u0000btitle\";N;s:8:\"\u0000*\u0000title\";N;s:8:\"\u0000*\u0000place\";N;s:6:\"\u0000*\u0000pub\";N;s:10:\"\u0000*\u0000edition\";N;s:9:\"\u0000*\u0000tpages\";N;s:9:\"\u0000*\u0000series\";N;s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";N;}"
Unpaywall access
"O:16:\"EuropePMCOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:17:\"10.1159\/000138977\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:229:\"Modified CAPOX (Capecitabine plus Oxaliplatin) Regimen Every Two Weeks as Second-Line Treatment in Patients with Advanced Colorectal Cancer Previously Treated with Irinotecan-Based Frontline Therapy : A Multicenter Phase II Study\";s:9:\"\u0000*\u0000jtitle\";s:8:\"Oncology\";s:9:\"\u0000*\u0000stitle\";s:8:\"Oncology\";s:7:\"\u0000*\u0000date\";s:4:\"2008\";s:9:\"\u0000*\u0000volume\";s:2:\"74\";s:8:\"\u0000*\u0000issue\";s:3:\"1-2\";s:8:\"\u0000*\u0000spage\";s:2:\"31\";s:8:\"\u0000*\u0000epage\";s:2:\"36\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0030-2414\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:9:\"KAKOLYRIS\";s:10:\"\u0000*\u0000aufirst\";s:1:\"S\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:11:{i:0;s:12:\"SOUGLAKOS, J\";i:1;s:11:\"VARDAKIS, N\";i:2;s:14:\"GEORGOULIAS, V\";i:3;s:10:\"POLYZOS, A\";i:4;s:12:\"ARDAVANIS, A\";i:5;s:8:\"ZIRAS, N\";i:6;s:15:\"ATHANASIADIS, A\";i:7;s:14:\"VARTHALITIS, I\";i:8;s:14:\"AMARANTIDIS, K\";i:9;s:10:\"TSOUSIS, S\";i:10;s:11:\"VAMVAKAS, L\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:229:\"Modified CAPOX (Capecitabine plus Oxaliplatin) Regimen Every Two Weeks as Second-Line Treatment in Patients with Advanced Colorectal Cancer Previously Treated with Irinotecan-Based Frontline Therapy : A Multicenter Phase II Study\";s:8:\"\u0000*\u0000place\";s:5:\"Basel\";s:6:\"\u0000*\u0000pub\";s:6:\"Karger\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"6\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Europe PubMed Central access
"O:11:\"BaseOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:17:\"10.1159\/000138977\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:229:\"Modified CAPOX (Capecitabine plus Oxaliplatin) Regimen Every Two Weeks as Second-Line Treatment in Patients with Advanced Colorectal Cancer Previously Treated with Irinotecan-Based Frontline Therapy : A Multicenter Phase II Study\";s:9:\"\u0000*\u0000jtitle\";s:8:\"Oncology\";s:9:\"\u0000*\u0000stitle\";s:8:\"Oncology\";s:7:\"\u0000*\u0000date\";s:4:\"2008\";s:9:\"\u0000*\u0000volume\";s:2:\"74\";s:8:\"\u0000*\u0000issue\";s:3:\"1-2\";s:8:\"\u0000*\u0000spage\";s:2:\"31\";s:8:\"\u0000*\u0000epage\";s:2:\"36\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0030-2414\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:9:\"KAKOLYRIS\";s:10:\"\u0000*\u0000aufirst\";s:1:\"S\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:11:{i:0;s:12:\"SOUGLAKOS, J\";i:1;s:11:\"VARDAKIS, N\";i:2;s:14:\"GEORGOULIAS, V\";i:3;s:10:\"POLYZOS, A\";i:4;s:12:\"ARDAVANIS, A\";i:5;s:8:\"ZIRAS, N\";i:6;s:15:\"ATHANASIADIS, A\";i:7;s:14:\"VARTHALITIS, I\";i:8;s:14:\"AMARANTIDIS, K\";i:9;s:10:\"TSOUSIS, S\";i:10;s:11:\"VAMVAKAS, L\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:229:\"Modified CAPOX (Capecitabine plus Oxaliplatin) Regimen Every Two Weeks as Second-Line Treatment in Patients with Advanced Colorectal Cancer Previously Treated with Irinotecan-Based Frontline Therapy : A Multicenter Phase II Study\";s:8:\"\u0000*\u0000place\";s:5:\"Basel\";s:6:\"\u0000*\u0000pub\";s:6:\"Karger\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"6\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Base Search access
"O:12:\"ArXivOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:17:\"10.1159\/000138977\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:229:\"Modified CAPOX (Capecitabine plus Oxaliplatin) Regimen Every Two Weeks as Second-Line Treatment in Patients with Advanced Colorectal Cancer Previously Treated with Irinotecan-Based Frontline Therapy : A Multicenter Phase II Study\";s:9:\"\u0000*\u0000jtitle\";s:8:\"Oncology\";s:9:\"\u0000*\u0000stitle\";s:8:\"Oncology\";s:7:\"\u0000*\u0000date\";s:4:\"2008\";s:9:\"\u0000*\u0000volume\";s:2:\"74\";s:8:\"\u0000*\u0000issue\";s:3:\"1-2\";s:8:\"\u0000*\u0000spage\";s:2:\"31\";s:8:\"\u0000*\u0000epage\";s:2:\"36\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0030-2414\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:9:\"KAKOLYRIS\";s:10:\"\u0000*\u0000aufirst\";s:1:\"S\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:11:{i:0;s:12:\"SOUGLAKOS, J\";i:1;s:11:\"VARDAKIS, N\";i:2;s:14:\"GEORGOULIAS, V\";i:3;s:10:\"POLYZOS, A\";i:4;s:12:\"ARDAVANIS, A\";i:5;s:8:\"ZIRAS, N\";i:6;s:15:\"ATHANASIADIS, A\";i:7;s:14:\"VARTHALITIS, I\";i:8;s:14:\"AMARANTIDIS, K\";i:9;s:10:\"TSOUSIS, S\";i:10;s:11:\"VAMVAKAS, L\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:229:\"Modified CAPOX (Capecitabine plus Oxaliplatin) Regimen Every Two Weeks as Second-Line Treatment in Patients with Advanced Colorectal Cancer Previously Treated with Irinotecan-Based Frontline Therapy : A Multicenter Phase II Study\";s:8:\"\u0000*\u0000place\";s:5:\"Basel\";s:6:\"\u0000*\u0000pub\";s:6:\"Karger\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"6\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
arXiv access
